CU24644B1 - ANTIBODY-DRUG CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS - Google Patents

ANTIBODY-DRUG CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS

Info

Publication number
CU24644B1
CU24644B1 CU2019000061A CU20190061A CU24644B1 CU 24644 B1 CU24644 B1 CU 24644B1 CU 2019000061 A CU2019000061 A CU 2019000061A CU 20190061 A CU20190061 A CU 20190061A CU 24644 B1 CU24644 B1 CU 24644B1
Authority
CU
Cuba
Prior art keywords
antibody
stem cells
hematopoietic stem
drug conjugates
ablation
Prior art date
Application number
CU2019000061A
Other languages
Spanish (es)
Other versions
CU20190061A7 (en
Inventor
Anthony E Boitano
Matthew Burger
Susan E Cellitti
Michael P Cooke
Catrin Finner
Bernhard Hubert Geierstanger
Yunho Jin
Si Tuen Lee-Hoeflich
Hongngoc Thi Pham
Siew Ho Schleyer
Kathrin Tissot
Tetsuo Uno
Ben Wen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20190061A7 publication Critical patent/CU20190061A7/en
Publication of CU24644B1 publication Critical patent/CU24644B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

<p>La presente invención proporciona conjugados anticuerpo-fármaco de fórmula (I)</p> <p> A-(L<sub>B</sub>-(D)n)y</p> <p>donde A es un fragmento de anticuerpo que específicamente se une a cKIT humano donde el fragmento de anticuerpo es un Fab o Fab' y se conecta a un agente citotóxico (D), a través de un enlazador (L) y el conjugado permite la ablación de células madres hematopoyéticas en un paciente que lo necesita.</p><p>The present invention provides antibody-drug conjugates of formula (I)</p> <p> A-(L<sub>B</sub>-(D)n)y</p> <p>where A is an antibody fragment that specifically binds to human cKIT where the antibody fragment is a Fab or Fab' and is linked to a cytotoxic agent (D), via a linker (L) and the conjugate allows ablation of hematopoietic stem cells in a patient who needs it.</p>

CU2019000061A 2016-12-21 2017-12-19 ANTIBODY-DRUG CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS CU24644B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437622P 2016-12-21 2016-12-21
US201762520854P 2017-06-16 2017-06-16
PCT/IB2017/058159 WO2018116178A1 (en) 2016-12-21 2017-12-19 Antibody drug conjugates for ablating hematopoietic stem cells

Publications (2)

Publication Number Publication Date
CU20190061A7 CU20190061A7 (en) 2020-03-04
CU24644B1 true CU24644B1 (en) 2023-02-13

Family

ID=60957364

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000061A CU24644B1 (en) 2016-12-21 2017-12-19 ANTIBODY-DRUG CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS

Country Status (23)

Country Link
US (2) US11357864B2 (en)
EP (1) EP3558389A1 (en)
JP (2) JP7181203B2 (en)
KR (1) KR20190099238A (en)
CN (2) CN117653740A (en)
AU (1) AU2017383458C1 (en)
BR (1) BR112019012483A2 (en)
CA (1) CA3045592A1 (en)
CL (1) CL2019001745A1 (en)
CO (1) CO2019006455A2 (en)
CR (1) CR20190296A (en)
CU (1) CU24644B1 (en)
EA (1) EA201991526A1 (en)
EC (1) ECSP19044625A (en)
IL (2) IL300567A (en)
JO (1) JOP20190155A1 (en)
MA (1) MA47231A (en)
MX (1) MX2019007582A (en)
MY (1) MY193985A (en)
PE (1) PE20191539A1 (en)
PH (1) PH12019501330A1 (en)
TW (2) TWI778994B (en)
WO (1) WO2018116178A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3452492A1 (en) * 2016-05-05 2019-03-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
MX2018015684A (en) * 2016-06-17 2019-08-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells.
AU2019283654A1 (en) * 2018-06-07 2021-01-28 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (ADCs)
AR115571A1 (en) * 2018-06-20 2021-02-03 Novartis Ag DRUG ANTIBODY CONJUGATES FOR HEMATOPOIETIC STEM CELL ABLATION
JP2021530546A (en) * 2018-07-23 2021-11-11 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
EP3826625A4 (en) * 2018-07-23 2022-08-24 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
JP2022512629A (en) * 2018-10-23 2022-02-07 マジェンタ セラピューティクス インコーポレイテッド Fc silenced antibody drug conjugate (ADC) and its use
WO2020089811A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
KR20210094610A (en) * 2018-11-26 2021-07-29 포티 세븐, 인코포레이티드 Humanized Antibodies to c-Kit
WO2020121071A1 (en) * 2018-12-12 2020-06-18 Levim Biotech Llp Acylation process for preparation of n-substituted peptide
MX2021014729A (en) * 2019-06-04 2022-02-25 Magenta Therapeutics Inc Methods and compositions for treating autoimmune diseases.
AU2019341066B1 (en) * 2019-08-07 2021-04-01 Mabplex International Co., Ltd. Antibody-drug conjugates and uses thereof
CN116183899B (en) * 2023-04-28 2023-06-30 天津市协和医药科技集团有限公司 Preparation method of acridinium ester marked antibody preservation solution

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DE69232706T2 (en) 1991-05-01 2002-11-28 Jackson H M Found Military Med METHOD FOR TREATING INFECTIOUS RESPIRATORY DISEASES
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
PT885002E (en) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
ES2301198T3 (en) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. ARTIFICIAL POLYPEPTIDES OF ANTIBODIES.
JP2002518432A (en) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド Large porous particles released from an inhaler
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
WO2004002425A2 (en) * 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
ES2347657T3 (en) 2003-03-24 2010-11-03 Zymogenetics, Inc. ANTIBODIES DIRECTED AGAINST IL-22RA AND ASSOCIATES OF UNION AND PROCEDURE OF USE IN INFLAMMATION.
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
ES2642205T3 (en) 2006-11-03 2017-11-15 The Board Of Trustees Of The Leland Stanford Junior University Selective immuno-impoverishment of a niche of endogenous graft stem cells
JP5918129B2 (en) 2009-06-22 2016-05-18 メディミューン，エルエルシー Engineered Fc region for site-specific conjugation
AR085091A1 (en) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc ANTI-KIT ANTIBODIES AND THEIR USES
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
CN115925957A (en) 2013-02-08 2023-04-07 Irm责任有限公司 Specific sites for modifying antibodies to make immunoconjugates
ES2701051T3 (en) 2013-03-15 2019-02-20 Novartis Ag Antibody-drug conjugates
JP2017509337A (en) * 2014-03-12 2017-04-06 ノバルティス アーゲー Specific sites for modifying antibodies that make immunoconjugates
CA2951368A1 (en) * 2014-06-13 2015-12-17 Novartis Ag Auristatin derivatives and conjugates thereof
US10786578B2 (en) * 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
US9938323B2 (en) * 2014-11-06 2018-04-10 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
EP4249916A3 (en) * 2015-04-06 2023-11-01 President and Fellows of Harvard College Compositions and methods for non-myeloablative conditioning
EP3310813A1 (en) * 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
MX2018015684A (en) 2016-06-17 2019-08-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells.

Also Published As

Publication number Publication date
RU2019122794A (en) 2021-01-22
IL267478A (en) 2019-08-29
TW202300524A (en) 2023-01-01
CN110099697A (en) 2019-08-06
KR20190099238A (en) 2019-08-26
AU2017383458A1 (en) 2019-06-13
JOP20190155A1 (en) 2019-06-23
MY193985A (en) 2022-11-04
EP3558389A1 (en) 2019-10-30
CA3045592A1 (en) 2018-06-28
MX2019007582A (en) 2019-09-06
AU2017383458C1 (en) 2021-08-12
PE20191539A1 (en) 2019-10-23
JP2020504112A (en) 2020-02-06
PH12019501330A1 (en) 2020-03-02
TWI778994B (en) 2022-10-01
CN110099697B (en) 2023-11-28
CL2019001745A1 (en) 2019-09-13
CN117653740A (en) 2024-03-08
MA47231A (en) 2019-10-30
US20220305134A1 (en) 2022-09-29
TW201828991A (en) 2018-08-16
IL267478B1 (en) 2023-03-01
US20190321483A1 (en) 2019-10-24
CO2019006455A2 (en) 2019-06-28
US11357864B2 (en) 2022-06-14
EA201991526A1 (en) 2020-01-24
JP7181203B2 (en) 2022-11-30
CU20190061A7 (en) 2020-03-04
ECSP19044625A (en) 2019-06-30
AU2017383458B2 (en) 2021-04-29
IL267478B2 (en) 2023-07-01
CR20190296A (en) 2019-09-13
BR112019012483A2 (en) 2020-04-14
WO2018116178A1 (en) 2018-06-28
JP2023015080A (en) 2023-01-31
RU2019122794A3 (en) 2021-10-12
IL300567A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
CU24644B1 (en) ANTIBODY-DRUG CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS
CO2018004152A2 (en) Antibody-pyrrolobenzodiazepine drug conjugates and methods of use
BR112018014615A2 (en) ror1 antibody compositions and related methods
CL2016001514A1 (en) Antibody-drug conjugate that possesses a non-peptide chemical moiety, which can be cleaved by cathepsin b; use for the manufacture of a useful drug and pharmaceutical conjugation.
AR096015A1 (en) CONJUGATES OF DRUGS WITH ANTIBODIES
CL2016002585A1 (en) Immunoconjugate comprising an antigen-binding protein that binds to maturation antigen of lymphocytes b (bcma) and a cytotoxic agent, pharmaceutical composition and its use (divisional application 201303373)
PE20160671A1 (en) ANTI-CXCR4 ANTIBODIES AND ANTIBODY AND DRUG CONJUGATES
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
BR112015027309A2 (en) antibody, composition, method of treatment and use of an antibody
AR080795A1 (en) ANTI-LRP6 ANTIBODIES (PROTEIN RELATED TO THE LDL RECEIVER TYPE 6)
CO2017004782A2 (en) Antibody-drug conjugates
AR095666A1 (en) CONJUGATES OF DRUGS WITH ANTIBODIES
EA201691059A1 (en) PEPTIDOMYMETICS COMPOUNDS AND THEIR CONJUGATES CONTAINING ANTIBODY AND MEDICINE
AR091703A1 (en) ANTIBODIES AND IMMUNOCATE PLAYERS INCLUDING ANTI-CD22 ANTIBODIES
BR112015030514A2 (en) COMPOSITIONS AND METHODS FOR CONJUGATION OF ACTIVABABLE ANTIBODIES
BR112015023391A8 (en) anti-egfr antibody-drug conjugate formulations
CR20110566A (en) IMMUNOCONJUGADOS OF ANTIMESOTELINA AND USES OF THE SAME
CL2018000131A1 (en) Il22&#39;s immunoconjugates
CL2018001334A1 (en) Antibodies and anti-5t4 antibody-drug conjugates.
BR112021008012A2 (en) Engineered cysteine antibody-drug conjugates with peptide-containing linkers
BR112015027474A2 (en) obinutuzumab, composition, obinutuzumab in combination with the anti-cd22 anti-cd22-mc-vc-pab-mmae cd22 antibody-drug conjugate and use of obinutuzumab in combination with the anti-cd22-mc-vc-pab-cd22 antibody-drug conjugate mmae
BR112019023909A8 (en) USE OF AN IMMUNOCONJUGATE THAT BINDS FOLR1, AND, USE OF AN IMMUNOCONJUGATE THAT BINDS FOLR1 AND PEMBROLIZUMAB
BR112018076639A2 (en) combination chemotherapies
EA202091161A1 (en) ANTIBODY CONJUGATES AGAINST CD22 WITH MYTANZINE, THEIR COMBINATIONS AND METHODS OF APPLICATION
ECSP21044421A (en) ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF